CareDx Reports Strong Q3 2026 Results with Significant Revenue Growth and Raised Full-Year Guidance
CareDx (CDNA) delivered robust third-quarter 2026 financial results, headlined by a 39% year-over-year increase in total revenue to $139 million. The growth was primarily fueled by a 65% surge in testing services following the NavDx acquisition and expanded transplant monitoring volumes. Adjusted EBITDA doubled to $30 million, representing a 22% margin, as the company benefited from increased revenue per test and disciplined expense management. Driven by strong performance across its testing segments and specialty oncology integration, management raised its full-year 2026 guidance for both revenue ($520M–$530M) and Adjusted EBITDA ($90M–$100M). Despite these gains, leadership noted ongoing challenges in the revenue cycle, specifically regarding payer resistance to reimbursement for diagnostic tests.
Topics: Acquisition Impact EBITDA Financial Guidance Revenue Growth Testing Volume